Update: Tarloxotinib advances into two Phase II trials
Tarloxitinib (TH-4000), Threshold’s earlier-stage hypoxia asset, has now started two Phase II studies, as planned. With active development now ongoing we include an indicative valuation for this asset in our rNPV, which has increased to $1,023m ($14.3/share). Tarloxotinib broadens and diversifies Threshold’s pipeline beyond evofosfamide, where we continue to expect the number of events needed for analysis of the Phase III STS and pancreatic trials should be reached in H215, with data shortly after.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.